CASE REPORT 2: HYPERKALEMIA Case Description A 79-year-old man with type 2 diabetes was receiving in-centre IHD 3 times weekly
Not only did their weight decrease, but they experienced lower fasting insulin levels and better HOMA-IR scores, indicating improved insulin sensitivity
"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials"
Now, it is also FDA-approved to help with weight loss in adults with a BMI greater than or equal to 30 mg/kg alone or 27 mg/kg with at least one weight-related comorbidity such as insulin resistance, hypertension, high cholesterol, heart disease, and gout
Telemedicine lowers a barrier for patients who may be reluctant to ask their health care provider in person to put them on a weight loss drug, he notes